AAV is a single stranded DNA virus which has shown great promise as a gene therapy vector. In clinical trial, rAAV vectors delivering RPE65 gene have been demonstrated to cure Leber's congenital amaurosis (LCA) diseases and patients are able to regain normal vision after receiving the vectors. However, its use in other genetic diseases such as hemophilia still face considerable challenge. Systemic delivery of rAAV into human subjects would require a lot more vectors than targeting the retina tissue. Prelimary studies have demonstrated more than 99.9% of rAAV vectors were wasted in the varous stages of rAAV transduction. In addition, rAAV genomes packaging preference remains an unsettling issues. In order to further develop recombinant AAV for human gene therapy, we hypothesize that it would eliminate unwanted replication competent AAV particle formation and improve rAAV production by sequetering the helper function and vector sequencing into different cellular compartment. Advanced genomics and proteomics will be introduced to study rAAV packaging preference and encapsidation mechanism. Finally, we identified that cytoplasm is major site for rAAV genome loss. An innovative assay will be established to track rAAV genomes in cytoplasm host and mechanism will be studied to reduce rAAV genomes in cytoplasm of the host cells. Hence, our three specific aims are 1. To develop and optimize the next generation of rAAV packaging system~ 2. To characterize rAAV genome integrity and rAAV packaging mechanisms~ 3. To study the molecular status of recombinant AAV genomes in the cytoplasm. Completion of specific aims in this application will markedly enhance the way of rAAV vectors to be used in the human gene therapy field.

Public Health Relevance

The completion of this project may provide a solution for producing high quality rAAV vector economically. Our work may help design optimized vector for human gene therapy and improve the quality of life of patients with genetic diseases.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BST-N (90))
Program Officer
Mcdonald, Cheryl
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Schools of Medicine
United States
Zip Code
Wang, Qizhao; Dong, Biao; Pokiniewski, Katie A et al. (2017) Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors. Mol Ther Methods Clin Dev 4:149-158
Wang, Qizhao; Wu, Zhongren; Zhang, Junping et al. (2017) A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors. Mol Ther Methods Clin Dev 7:146-156
Wang, Qizhao; Firrman, Jenni; Wu, Zhongren et al. (2016) High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction. Hum Gene Ther 27:971-981
Wang, Q; Dong, B; Firrman, J et al. (2016) Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment. Gene Ther 23:597-605
Moore, Andrea R; Dong, Biao; Chen, Lingxia et al. (2015) Vaccinia virus as a subhelper for AAV replication and packaging. Mol Ther Methods Clin Dev 2:15044
Dong, Biao; Duan, Xunbao; Chow, Hoi Yee et al. (2014) Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors. PLoS One 9:e86453
Dong, Biao; Moore, Andrea R; Dai, Jihong et al. (2013) A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res 41:6609-17
St Laurent, Georges; Shtokalo, Dmitry; Dong, Biao et al. (2013) VlincRNAs controlled by retroviral elements are a hallmark of pluripotency and cancer. Genome Biol 14:R73
Kapranov, Philipp; Chen, Lingxia; Dederich, Debra et al. (2012) Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 23:46-55
Roberts, Sean A; Dong, Biao; Firrman, Jenni A et al. (2011) Engineering Factor Viii for Hemophilia Gene Therapy. J Genet Syndr Gene Ther 1:

Showing the most recent 10 out of 15 publications